Dutch Health Council: Delaying Trans Youth Care Is 'Morally Urgent' to Fix

The Health Council of the Netherlands, the government’s top scientific advisory body on health policy, has concluded a two-year review of gender-affirming care for trans youth with a clear finding: the treatment fits within the country’s existing health law framework, and leaving young people on long waitlists without care is not a neutral choice.

The review was commissioned in May 2024 and chaired by Professor Olaf Dekkers of Leiden University Medical Center. Its central conclusion, in the council’s own words, is that “non-treatment is therefore not a neutral option” — a direct rebuttal to the argument, increasingly common in other countries’ policy debates, that pausing or withholding hormonal treatment for trans minors is simply the cautious default.

What the review found

The committee’s report cites regret rates for youth who started puberty blockers between 0% and 3.5% — those who later discontinued treatment. It also found that after starting puberty blockers, young patients reported measurable mental health improvements: fewer depressive symptoms, reduced suicidality, and less self-harm. On the physical side, the review found the treatment achieved its intended effects and that current data on negative physical or mental side effects were, in the committee’s words, “not concerning.”

The report’s most pointed line addresses timing directly: “shortening the waiting times is morally urgent,” it states, because delayed care limits adolescents’ development and forecloses opportunities during a period of life that doesn’t wait for a clinic appointment to open up.

Why this lands differently than the UK’s Cass Review

The Dutch review arrives loaded with context, because it reaches nearly the opposite conclusion of the UK’s 2024 Cass Review, which recommended against hormone treatment for most trans minors outside of clinical trials and reshaped policy across England and Wales. The two reviews aren’t assessing identical systems: the Netherlands uses what’s often called a “step-by-step exploration” model, built on the original Dutch Protocol developed at Amsterdam’s VU University Medical Center in the 1990s, which requires extensive psychological and diagnostic assessment before any medical treatment begins. That’s a different starting point than the informal, faster-moving referral pathways that drew scrutiny in the UK review.

Even so, the practical effect of the Dutch conclusion is to push back against a narrative — amplified in the US, the UK, and increasingly in parts of continental Europe — that the clinical and scientific consensus on youth gender-affirming care is collapsing or has already shifted decisively toward restriction. The country that pioneered the modern treatment protocol for trans youth just spent two years re-examining its own evidence base and came back recommending faster access, not less of it.

Why it matters beyond the Netherlands

For a European LGBTQ+ readership watching trans healthcare access narrow in some places and hold steady in others, the Dutch review is a useful data point precisely because of who produced it: not an advocacy organization, but the government’s own scientific advisory council, working from clinical outcomes data gathered over years. It doesn’t resolve the broader political fight — Portugal’s parliament, for instance, has been advancing bills this year that would restrict gender-affirming care for trans youth and require medical sign-off for adults changing legal documents — but it does complicate any claim that the science itself has turned against treatment.

Whether the Dutch government moves to actually shorten the waitlists the council flagged as the real problem remains an open question, and one worth watching as European countries continue to diverge sharply on this issue depending on which government committee — and which country — is doing the asking.

Sources: LGBTQ Nation, Erin in the Morning.